Bio-Rad Laboratories, Inc. Class A Common Stock vs Vanguard Real Estate Index Fund ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.53 (market cap $9.43B), while Vanguard Real Estate Index Fund ETF trades at $97.18. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BIO | VNQ | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | — |
52-Week High | $356.25 | $100.95 |
52-Week Low | $241.71 | $87.00 |
Enterprise Value | $9.18B | — |
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
VNQ (Vanguard Real Estate ETF) trades at $96.745, down 0.38% on the day amid a bearish technical signal. The ETF shows mixed momentum with oversold short-term RSI readings but bearish moving averages. Recent institutional selling activity from firms like Bank of America and City Holding Co. indicates cautious positioning in the real estate sector. The fund's dividend yield remains a key attraction for income-focused investors.
The outlook for VNQ is challenged by rising interest rate sensitivity and institutional outflows, though the oversold RSI suggests potential for near-term stabilization. Investors should weigh the ETF's low expense ratio and U.S. REIT diversification against sector-specific headwinds including commercial real estate pressures and economic uncertainty.
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →